Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James More >
"We are very excited about RNN; it's an early-stage oncology company with multiple shots on goal." (7/31/14) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Christopher James More >
Ed Arce joined MLV & Co. in April 2011 as an equity analyst in the Life Sciences Equity Research group, covering biotechnology, biopharmaceutical and specialty pharmaceutical companies. Prior to joining MLV, he worked as a senior research associate at Wedbush Securities and UBS Securities, covering the biotechnology and U.S. large-cap pharmaceutical industries, respectively. Arce started his equity research career in 2005 as a research associate at First Albany Capital (now Gleacher & Co.), covering specialty and generic pharmaceutical companies. Arce holds a master's degree in inance from Boston College. In addition, he holds a bachelor's degree in civil engineering from Florida International University (FIU), and is a graduate of the executive master's degree program in business administration at the Chapman Graduate School of Business at FIU. Arce is a board-licensed professional engineer (PE), and a level III CFA candidate.
What Moves Biotech Stocks? Ed Arce Has Answers. (10/18/12) Biotech stocks move on material news, which means clinical data, regulatory progress, new partnerships and big contracts with new customers. Analyst Ed Arce of MLV & Co. holds to these principles as he shares compelling biotech names in this exclusive interview with The Life Sciences Report.